Curated News
By: NewsRamp Editorial Staff
October 09, 2024
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Discuss on Reddit
Discuss on LinkedInTLDR
- Silexion Therapeutics Corp. to present at 2024 Maxim Healthcare Virtual Summit, gaining exposure and potential investment opportunities.
- Silexion Therapeutics will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, featuring the CEO and Chief Scientific Officer.
- Silexion Therapeutics' innovative RNA interference therapies for KRAS-driven cancers aim to improve patient outcomes and treat difficult-to-treat cancers.
- Silexion Therapeutics is developing cutting-edge RNA interference therapies for solid tumors and actively participating in healthcare summits to share their progress.
Impact - Why it Matters
This news matters as it highlights Silexion Therapeutics' participation in a significant healthcare summit, showcasing their innovative RNAi therapies for difficult-to-treat cancers, which could potentially improve outcomes for patients.
Summary
Silexion Therapeutics Corp. (NASDAQ: SLXN) will participate in the 2024 Maxim Healthcare Virtual Summit, with CEO Ilan Hadar and CSO Dr. Mitchell Shirvan joining a fireside chat. The event will be streamed live on M-Vest and accessible to members via this link.
The company's management team will be available for one-on-one meetings throughout the summit, and interested investors are encouraged to contact their Maxim representative to schedule a meeting. Silexion is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, with a focus on improving outcomes for patients with difficult-to-treat cancers.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
